NRC-2694-A
NRC-2694-A is an orally effective EGFR tyrosine kinase inhibitor. NRC-2694-A can be used in the study of malignant squamous cell carcinoma (HNSCC) [1].
Product Specifications
CAS Number
1172626-99-1
UNSPSC
12352005
Target
EGFR
Type
Reference compound
Related Pathways
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/nrc-2694-a.html
Smiles
COC1=CC2=NC=NC(NC3=CC=CC(C#C)=C3)=C2C=C1OCCCN4CCOCC4.Cl
Molecular Formula
C24H27ClN4O3
Molecular Weight
454.95
References & Citations
[1]Adkins D, et al. Oral NRC-2694-A in combination with paclitaxel as therapy for recurrent and/or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) that progressed on or after an immune checkpoint inhibitor (ICI) : A multi-center, single-arm, phase 2 trial. 2023.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 2
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
VAng-Ly3089-500gEcoli 500 µg (E. coli)
Recombinant Caenorhabditis Elegans C02F5.5 Protein (aa 1-173)
Sign In for Pricing
View Details 
32-8549-50 50 µg
Recombinant Human IL-2 Receptor Subunit a/IL-2RA/CD25 (C-Fc)
Sign In for Pricing
View Details